Beta Bionics Sued for Misleading Statements About Insulin Pump

LOS ANGELES, Sept. 8, 2026 /CourierPR/ -- Beta Bionics, Inc., a company listed on the NASDAQ under the ticker symbol BBNX, has been sued for securities law violations by the DJS Law Group. The lawsuit, filed on behalf of shareholders, alleges that the company made false and misleading statements regarding the safety and efficacy of its iLet Bionic Pancreas insulin pump during the class period from July 30, 2025, to February 24, 2026.

According to the complaint, Beta Bionics repeatedly assured investors that the FDA's Form 483, which was issued following an inspection of the company’s manufacturing facility, did not reflect any underlying problems with the iLet device. The company claimed that the FDA’s findings were merely procedural and that the events the company failed to report were minor and required no medical intervention. However, the complaint states that the FDA’s findings actually covered the company’s quality management system, its investigation and correction of known device malfunctions, and the risk analysis for the device itself. The unreported events, the complaint alleges, included serious injuries.

The DJS Law Group, led by David Schwartz, a founding partner of Schall Brown & Schwartz LLP, is representing shareholders who purchased BBNX shares during the class period and suffered losses as a result of the alleged misrepresentations. The firm specializes in securities class actions and corporate governance litigation, with a focus on enhancing investor return through aggressive advocacy.

Schwartz commented, "Beta Bionics' public statements were false and materially misleading throughout the class period. Shareholders who purchased BBNX during the relevant period are encouraged to contact the firm to discuss their rights and potential lead plaintiff appointments."

The complaint also highlights that Beta Bionics continued to reassure investors about the FDA's concerns even as further information emerged, showing that the unreported events were far more serious than the company had initially represented. Additionally, the FDA’s objections were not confined to a difference in regulatory interpretation, but rather reflected deeper issues with the company’s operations.

Investors who purchased BBNX shares between July 30, 2025, and February 24, 2026, and suffered a loss are encouraged to contact the DJS Law Group. The deadline for filing a lead plaintiff application is November 3, 2026.

For those interested in learning more about the case or seeking legal advice, the DJS Law Group can be reached through their website or by contacting their office at 274 White Plains Road, Suite 1.